Indeed, Concurrent deletion of PAX5 and CDKN2A/2B suggests that there are common targets in the pathogenesis of BCP-ALL (Kim et al., 2011; Schwab et al., 2013). This evidence concerns the gene PAX5 and acute lymphoblastic leukemia.